Immunocore, one of UK biotech's brightest hopes ... and the first CAR-T therapies from Novartis and Kite Pharma, anticipated to gain approval in late 2017/ early 2018. The privately-held, Oxford ...

The healthcare industry is set for growth due to advancements in targeted treatments and personalized care and the rapid ...

Immunocore has a portfolio displaying its use in treating cancer, autoimmune diseases and other infectious diseases, and is collaborating with a number of big pharma companies. It has just ...

GlobalData, the parent company of Pharmaceutical Technology, estimates that Kimmtrak will bring in $552m in 2029. "Immunocore and BMS partner to investigate first-line treatment for melanoma" was ...

Immunocore Holdings has dosed the first subject in a multicentre Phase I/II trial of IMC-R117C, a PIWIL1-targeted immunotherapy, for treating colorectal and other gastrointestinal cancers.

Immunocore (IMCR) Holdings announces that the first patient has been dosed in the Phase 1 trial of IMC-P115C which is a half-life extended ImmTAC candidate. IMC-P115C was developed to improve ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 6 January 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a ...

Immunocore (IMCR) Holdings set out its strategic priorities for 2025 including its plans for reaching more patients with melanoma and other diseases with high unmet needs. The Company also ...

Immunocore Holdings plc has appointed Travis Coy as Executive Vice President, Chief Financial Officer, and Head of Corporate Development effective January 1, 2025. Coy, who has over 20 years of ...

Ratings for Immunocore Hldgs (NASDAQ:IMCR) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview ...

Short interest in Immunocore Holdings PLC (NASDAQ:IMCR) decreased during the last reporting period, falling from 7.06M to 6.73M. This put 15.32% of the company's publicly available shares short.